FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY

Jyotsna Kapoor, Narendra Agrawal, Rayaz Ahmad, Sanjeev Kumar Sharma, Anshul Gupta, Dinesh Bhurani
  • Jyotsna Kapoor
    Affiliation not present
  • Narendra Agrawal
    Affiliation not present
  • Rayaz Ahmad
    Affiliation not present
  • Sanjeev Kumar Sharma
    Affiliation not present
  • Anshul Gupta
    Affiliation not present

Abstract

Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia(CML) to maximise treatment effectiveness. The main objective is to measure adherence to    IM & to evaluate individual patient characteristics, personal, treatment related &                    psychological factors influencing adherence behaviour. Hundred patients  receiving IM were analysed for adherence behaviour using 9 item Morisky Medication Adherence Scale              (9-MMAS) . Various factors were assessed for their impact on adherence behaviour.  These   factors were age, gender, duration of treatment, frequency & dosing of treatment, use  of        tobacco & alcohol, educational qualification,employment status,monthly  income, side effects, financial assistance in treatment, social support, knowledge about medicine & disease,         concomitant drug burden, polypharmacy, physician patient interaction, patient  educational    sessions & prevalence of depression. Seventy five percent of patients were found to be           adherent. On univariate analysis, prevalence of depression (p<0.000001), moderate severe     depression (p<0.000001), concomitant drug burden (p=0.036) & monthly income (p=0.015) were found to be significantly influencing adherence. The final multivariate model retained   prevalence of depression with OR= 10.367  (95% CI, 3.112- 34.538) as independent predictor of adherence to therapy. This study suggests that identification & treatment of depression among CML patients may further enhance adherence to IM therapy.

Keywords: Chronic Myeloid Leukemia, Adherence, Imatinib, Nine Item Morisky Medication Adherence Scale, Patient Health Questionnaire -9.

Keywords

Chronic Myeloid Leukemia, Adherence, Imatinib, Nine Item Morisky Medication Adherence Scale, Patient Health Questionnaire - 9.

Full Text:

PDF
HTML
Submitted: 2014-09-11 07:50:10
Published: 2015-02-12 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar

References

Druker BJ ,Guilhot F , O’ Brien SG et al . Five year follow up of patients receiving imatinib for chronic myeloid leukemia . N Eng J Med 2006 ; 355 : 2408-2417 .

Kantarjian HM , Cortes J , La Rosee P , Hochhaus A . Optimising therapy for patients with chronic myelogenousleukemia in chronic phase. Cancer 2010 ; 116 : 1419 -1430.

Marin D , Bazeos A , Mahon FX , Eliasson L , Milojkovic D , Blea M , Apperley JF , Syzdlo R et al . Adherence is the critical factor achieving molecular responses in patients with chronic myeloid leukemia who have achieve complete cytogenetic responses on imatinib. J Clin Oncol28 : 2381 – 2388.

Noens L , van Lierde MA , De Beck R et al. Prevalence , determinants , and outcome of non adherence to imatinib therapy in patients with chronic myeloid leukemia : The ADAGIO Study. Blood 2009 ;113 : 5401 -5411.

Darkow T ,Henk HJ , Thomas SK , et al. Treatment interruptions and non adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenousleukemia . Pharmacoeconomics 2007 ; 25 :481 -496.

Ibrahim AR , Eliasson L , Apperley JF , Milojkovic D , Bua M , Syzdlo R et al . Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long term therapy. Blood 2011 ; 117 (14) : 3733 – 6.

Ganesan P , Sagar TG , Dubashi B , Rajendranath R , Kannan K , Cyriac S et al . Non adherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia . Am J Hematol . 2011 ; 86 (6) :471 -4.

Jonsson S , Olsson B , Soderberg J , Wadnenvik H . Good adherence to imatinib therapy among patients with chronic myeloid leukemia – a single center observational study. Ann Hematol 2012 , 91 : 679- 685.

Campos Dos Reis S , de SouzeQuixada A , Nune S , CAmelocid MD , deSouza J , deCosta C et al. Adherence to imatinib in chronic myeloid leukemia : a study of first decade of responses obtained at a Brazilian Hospital. Rev Bras Hematol Hemoter . 2013 35 (3) :174-9.

Sodergard B , Halvarsson M , Tully MP , Mindouri S , Nordstom ML , Lindback S , et al. Adherence to treatment in Swedish HIV – infected patients . J Clin Pharm Ther2006 , 31 : 605 – 616.

Morisky DE , Green LW , Levin DM . Concurrent and predictive validity of a self reported measure of medication adherence . Med Care 1986 , 24 : 67-74.

Morisky DE ,Ang A , Krousal – Wood M , Ward HJ . Predictive validity of a medication adherence measure in an outpatient setting . J ClinHypertens 2008 , 10 : 348 – 354.

Santoleri F ,Sorice P , Lasala R , Rizzo CR , Constantini A . Patient adherence and persistence with imatinib ,nilotinib , dasatinib in clinical practice. Plos One 2013 , 8 ; issue 2 .

Krousal Wood M ,Hyre A , Muntner P , Morisky D . Methods to improve medication adherence in patients with hypertension : Current status and future directions. CurrOpiCardiol2005 , 20 : 296 – 300.

Dimatteo MR, Leeper HS , Croghan TW. Depression is a risk factor for non compliance with medical treatment :Meta analysis of the effects of anxiety and depression on patient adherence . Archives of Internal Medicine 2000 , 160 (14) : 210 -217.

Kumar R BP, Dudala S Rao , Rao AR . Kuppuswamy’s Socioeconomic Status – A revision Of Economic Pattern 2012 . International Journal Of Research and Development Of Health 2013 ,Vol 1(1) ; 2-4.

Abstract views:
201

Views:
PDF
200
HTML
1106

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185